Tim Watkins, who serves as Chief Medical Officer and Head of Development at Contineum Therapeutics, Inc. (NASDAQ: CTNM), completed a sale of 3,611 shares of the company’s Class A Common Stock on March 2, 2026. The disposition generated approximately $54,220 based on a weighted average sale price of $15.0153 per share, with executed trades spanning prices from $14.60 to $15.41.
On that same date, Watkins exercised options to acquire 3,611 shares of Class A Common Stock at an exercise price of $4.50, representing an aggregate exercise value of $16,249. Both the option exercise and the share sale were carried out pursuant to a pre-arranged 10b5-1 trading plan that Watkins adopted on September 23, 2025. After the sale, Watkins directly holds zero shares of Class A Common Stock.
Contineum’s market price was trading at $15.34 at the time of the report, situated close to a 52-week high of $16.33 and reflecting a one-year gain of 118%.
Separately, Contineum Therapeutics disclosed the pricing of an upsized public offering consisting of 7,346,938 shares of its Class A common stock at $12.25 per share, intended to raise approximately $90 million in gross proceeds. This upsized deal follows an earlier filing for a $75 million public offering, which included an underwriter option to purchase an additional $11.25 million of stock.
On the equity research front, Morgan Stanley revised its recommendation on Contineum, moving the stock from Overweight to Equalweight and cutting its price target from $23.00 to $14.00. The firm cited results from Contineum’s PIPE-307 Phase 2 VISTA study in relapsing-remitting multiple sclerosis, which did not demonstrate significant changes in low contrast letter acuity. The study outcome has shifted investor focus to another program in the pipeline, the LPA1R antagonist PIPE-791.
In addition to the corporate transactions and analyst action, InvestingPro provided an assessment indicating that CTNM appears overvalued at current levels and noted the availability of 11 additional ProTips and more extensive Pro Research Reports for deeper analysis ahead of the company’s March 5 earnings release.
Contextual note - The insider sale and option exercise were executed under an established 10b5-1 plan. The company is concurrently pursuing capital through a priced public offering and has recently received an analyst downgrade tied to clinical trial results.
The sequence of insider activity, capital markets action, and research reassessment underscores several active dynamics around Contineum Therapeutics as it approaches upcoming corporate disclosures.